I
Ian Hickson
Researcher at Janssen Pharmaceutica
Publications - 41
Citations - 9046
Ian Hickson is an academic researcher from Janssen Pharmaceutica. The author has contributed to research in topics: Chinese hamster ovary cell & DNA damage. The author has an hindex of 21, co-authored 39 publications receiving 8100 citations. Previous affiliations of Ian Hickson include Newcastle University & University of Florida.
Papers
More filters
Journal ArticleDOI
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
Hannah Farmer,Nuala McCabe,Christopher J. Lord,Andrew Tutt,Andrew Tutt,Damian A. Johnson,Tobias B. Richardson,Manuela Santarosa,Krystyna J. Dillon,Ian Hickson,Charlotte Knights,Niall M. B. Martin,Stephen P. Jackson,Graeme C. M. Smith,Alan Ashworth +14 more
TL;DR: BRCA1 or BRCA2 dysfunction unexpectedly and profoundly sensitizes cells to the inhibition of PARP enzymatic activity, resulting in chromosomal instability, cell cycle arrest and subsequent apoptosis, illustrating how different pathways cooperate to repair damage.
Journal ArticleDOI
Identification and characterization of a novel and specific inhibitor of the ataxia-telangiectasia mutated kinase ATM.
Ian Hickson,Yan Zhao,Caroline Richardson,Sharon J. Green,Niall M. B. Martin,Alisdair I. Orr,Philip Michael Reaper,Stephen P. Jackson,Nicola J. Curtin,Graeme C. M. Smith +9 more
TL;DR: KU-55933 is a novel, specific, and potent inhibitor of the ATM kinase, which did not potentiate the cytotoxic effects of ionizing radiation on ataxia-telangiectasia cells, nor did it affect their cell cycle profile after DNA damage.
Journal ArticleDOI
AZD8055 Is a Potent, Selective, and Orally Bioavailable ATP-Competitive Mammalian Target of Rapamycin Kinase Inhibitor with In vitro and In vivo Antitumor Activity
Christine M. Chresta,Barry R. Davies,Ian Hickson,Thomas Harding,Sabina Cosulich,Susan E. Critchlow,John Vincent,Rebecca Ellston,Darren Jones,Patrizia Sini,Dominic I. James,Zoe Howard,Phillippa Dudley,Gareth M. Hughes,Lisa Smith,Sharon Maguire,Marc Geoffrey Hummersone,Karine Malagu,Keith Allan Menear,Richard O. Jenkins,Matt Jacobsen,Graeme C. M. Smith,Sylvie Guichard,Martin Pass +23 more
TL;DR: AZD8055 is described, a novel ATP-competitive inhibitor of mTOR kinase activity, with an IC50 of 0.8 nmol/L, which results in significant growth inhibition and/or regression in xenografts, representing a broad range of human tumor types.
Journal ArticleDOI
Discovery of 4-{4-[(3R)-3-Methylmorpholin-4-yl]-6-[1-(methylsulfonyl)cyclopropyl]pyrimidin-2-yl}-1H-indole (AZ20): A Potent and Selective Inhibitor of ATR Protein Kinase with Monotherapy in Vivo Antitumor Activity
Kevin Michael Foote,Kevin Blades,Anna Cronin,Shaun M. Fillery,Sylvie S. Guichard,Lorraine A. Hassall,Ian Hickson,Xavier Jacq,Philip J. Jewsbury,Thomas M. McGuire,J. Willem M. Nissink,Rajesh Odedra,Ken Page,Paula Perkins,Abid Suleman,Kin Yip Tam,Pia Thommes,Rebecca Broadhurst,Christine M. Wood +18 more
TL;DR: The discovery and synthesis of a series of sulfonylmorpholinopyrimidines that show potent and selective ATR inhibition are described that leads to compound 6 (AZ20) which inhibits ATR immunoprecipitated from HeLa nuclear extracts with an IC50 of 5 nM.
Journal ArticleDOI
JNJ-26481585, a Novel “Second-Generation” Oral Histone Deacetylase Inhibitor, Shows Broad-Spectrum Preclinical Antitumoral Activity
Janine Arts,Peter King,Ann Marien,Wim Floren,Ann Beliën,Lut Janssen,Isabelle Noëlle Constance Pilatte,Bruno Roux,Laurence Decrane,Ron Gilissen,Ian Hickson,Veronique Vreys,Eugene Cox,Kees Bol,Willem Talloen,Ilse Goris,Luc Andries,Marc Du Jardin,Michel Janicot,Martin John Page,Kristof Van Emelen,Patrick Angibaud +21 more
TL;DR: The potent antitumor activity as a single agent in preclinical models combined with its favorable pharmacodynamic profile makes JNJ-26481585 a promising second-generation HDAC inhibitor.